Capital DailyCapital Daily
Markets · Investing · Business
Capital DailyCapital Daily
Finance

XLV vs. IHE: Which Healthcare ETF Is the Better Buy?

IHE's pharma-focused portfolio delivered higher returns over the past year, while XLV offers a broader healthcare focus with a much lower expense ratio.

XLV vs. IHE: Which Healthcare ETF Is the Better Buy?

Published July 31, 2026 · Category: Finance

Overview

The State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) provides broad healthcare exposure at a lower cost, while the iShares U.S. Pharmaceuticals ETF (NYSEMKT:IHE) offers a concentrated bet on U.S. drugmakers.

While both funds target health-related companies, they diverge sharply in portfolio construction, cost, and recent performance.

Details

Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-year return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.

Continue reading

Source

Originally published at www.fool.com.

Related Articles

CD
Capital Daily Newsroom

Capital Daily covers markets, crypto and commodities for Asia & the Middle East — tier-1 desk research, AI-driven analysis, institutional-grade data. Tip our newsroom: [email protected]

Email the newsroom →
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.